Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.

MLA

Liang Shi, et al. “Pathological Complete Response to Long-Course Neoadjuvant Alectinib in Lung Adenocarcinoma with EML4-ALK Rearrangement: Report of Two Cases and Systematic Review of Case Reports.” Frontiers in Oncology, July 2023, pp. 1–12. EBSCOhost, https://doi.org/10.3389/fonc.2023.1120511.

APA

Liang Shi, Shuhong Gao, Li Tong, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, & Zhe Liu. (2023). Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports. Frontiers in Oncology, 1–12. https://doi.org/10.3389/fonc.2023.1120511

Chicago

Liang Shi, Shuhong Gao, Li Tong, Qiyi Meng, Shijie Zhou, Daping Yu, Yujie Dong, and Zhe Liu. 2023. “Pathological Complete Response to Long-Course Neoadjuvant Alectinib in Lung Adenocarcinoma with EML4-ALK Rearrangement: Report of Two Cases and Systematic Review of Case Reports.” Frontiers in Oncology, July, 1–12. doi:10.3389/fonc.2023.1120511.